Chemotherapy-induced peripheral neuropathy in patients treated with taxanes and platinum derivatives

References

• de Moor JS, Mariotto AB, Parry C, Alfano CM, Padgett L, Kent EE, et al. Cancer survivors in the United States: Prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev 2013; 22:561–70.
   PubMed Web of Science ®Google Scholar
• NORDCAN: http://www-dep.Iarc.Fr/nordcan/. Cited 29th August 2014.
   Google Scholar
• Eckhoff L, Knoop AS, Jensen MB, Ejlertsen B, Ewertz M. Risk of docetaxel-induced peripheral neuropathy among 1,725 danish patients with early stage breast cancer. Breast Cancer Res Treat 2013;142:109–18.
   PubMed Web of Science ®Google Scholar
• Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, et al. Chemotherapy-induced peripheral neurotoxicity: A critical analysis. CA Cancer J Clin 2013; 63:419–37.
   PubMed Web of Science ®Google Scholar
• Argyriou AA, Kyritsis AP, Makatsoris T, Kalofonos HP. Chemotherapy-induced peripheral neuropathy in adults: A comprehensive update of the literature. Cancer Manag Res 2014;6:135–47.
   PubMed Web of Science ®Google Scholar
• Miltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: A comprehensive survey. Cancer Treat Rev 2014; 40:872–82.
   PubMed Web of Science ®Google Scholar
• Attal N, Bouhassira D, Gautron M, Vaillant JN, Mitry E, Lepere C, et al. Thermal hyperalgesia as a marker of oxaliplatin neurotoxicity: A prospective quantified sensory assessment study. Pain 2009;144:245–52.
   PubMed Web of Science ®Google Scholar
• Kroigard T, Schroder HD, Qvortrup C, Eckhoff L, Pfeiffer P, Gaist D, et al. Characterization and diagnostic evaluation of chronic polyneuropathies induced by oxaliplatin and docetaxel comparing skin biopsy to quantitative sensory testing and nerve conduction studies. Eur J Neurol 2014;21:623–9.
   PubMed Web of Science ®Google Scholar
• Vacca A, Ribatti D, Iurlaro M, Merchionne F, Nico B, Ria R, et al. Docetaxel versus paclitaxel for antiangiogenesis. J Hematother Stem Cell Res 2002;11:103–18.
   PubMedGoogle Scholar
• Schneider BP, Zhao F, Wang M, Stearns V, Martino S, Jones V, et al. Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. J Clin Oncol 2012;30:3051–7.
   PubMed Web of Science ®Google Scholar
• http://www.ema.europa.eu/ema/index.jsp?curl = pages/home/Home_Page.jsp. Cited 29th August 2014.
   Google Scholar
• Hershman DL, Weimer LH, Wang A, Kranwinkel G, Brafman L, Fuentes D, et al. Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 2011;125:767–74.
   PubMed Web of Science ®Google Scholar
• Osmani K, Vignes S, Aissi M, Wade F, Milani P, Levy BI, et al. Taxane-induced peripheral neuropathy has good long-term prognosis: A 1- to 13-year evaluation. J Neurol 2012; 259:1936–43.
   PubMed Web of Science ®Google Scholar
• Andersen KG, Jensen MB, Kehlet H, Gartner R, Eckhoff L, Kroman N. Persistent pain, sensory disturbances and functional impairment after adjuvant chemotherapy for breast cancer: Cyclophosphamide, epirubicin and fluorouracil compared with docetaxel + epirubicin and cyclophosphamide. Acta Oncol 2012;51:1036–44.
   PubMed Web of Science ®Google Scholar
• Albers JW, Chaudhry V, Cavaletti G, Donehower RC. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev 2014;3: CD005228.
   PubMed Web of Science ®Google Scholar
• Qvortrup C, Jensen BV, Fokstuen T, Nielsen SE, Keldsen N, Glimelius B, et al. A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine xelox(30) and chronomodulated xelox(30) as first-line therapy in patients with advanced colorectal cancer. Ann Oncol 2010;21:87–91.
   PubMed Web of Science ®Google Scholar
• Ramanathan RK, Rothenberg ML, de Gramont A, Tournigand C, Goldberg RM, Gupta S, et al. Incidence and evolution of oxaliplatin-induced peripheral sensory neuropathy in diabetic patients with colorectal cancer: A pooled analysis of three phase III studies. Ann Oncol 2010; 21:754–8.
   PubMed Web of Science ®Google Scholar
• Gregg RW, Molepo JM, Monpetit VJ, Mikael NZ, Redmond D, Gadia M, et al. Cisplatin neurotoxicity: The relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity. J Clin Oncol 1992;10:795–803.
   PubMed Web of Science ®Google Scholar
• Gamelin E, Gamelin L, Bossi L, Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: Current management and development of preventive measures. Semin Oncol 2002;29:21–33.
   PubMed Web of Science ®Google Scholar
• Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 2002;20:1767–74.
   PubMed Web of Science ®Google Scholar
• Park SB, Goldstein D, Lin CS, Krishnan AV, Friedlander ML, Kiernan MC. Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol 2009;27:1243–9.
   PubMed Web of Science ®Google Scholar
• Cavaletti G, Tredici G, Petruccioli MG, Donde E, Tredici P, Marmiroli P, et al. Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer 2001;37:2457–63.
   PubMed Web of Science ®Google Scholar
• Hershman DL, Lacchetti C, Dworkin RH, Lavoie Smith EM, Bleeker J, Cavaletti G, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American society of clinical oncology clinical practice guideline. J Clin Oncol 2014;32:1941–67.
   PubMed Web of Science ®Google Scholar
• Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: A randomized clinical trial. JAMA 2013;309:1359–67.
   PubMed Web of Science ®Google Scholar
• Mols F, Beijers T, Vreugdenhil G, van de Poll-Franse L. Chemotherapy-induced peripheral neuropathy and its association with quality of life: A systematic review. Support Care Cancer 2014;22:2261–9.
   PubMed Web of Science ®Google Scholar